ArticleIndian journal of thoracic and cardiovascular surgery2025
Tissue engineered decellularized bovine pericardium as prosthetic material in paediatric cardiac surgery.
Article in Indian journal of thoracic and cardiovascular surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bovine Pericardium Graft as a Salvage Option in Septoplasties at Risk of Septal Perforation.Journal of clinical medicine · 2025Article
- Congenital cardiac surgery: Innovations from India.Annals of pediatric cardiologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To evaluate the short-term outcomes of Tissue Engineered Decellularized Bovine pericardium (Synkroscaff®) in congenital heart surgery as a prosthetic material. Methodology: This is a prospective observational cohort study. SynkroScaff® was used as prosthetic material in cohort of successive patients under 18 years of age requiring cardiac surgery for congenital heart diseases. Patients were evaluated for residual shunt, infective endocarditis, stenosis, calcification and aneurysmal dilatation at discharge, after 1 month, 3 months, 6 months and 1 year post-operatively. Results: Ninety-two patients were included, and the patch was used in ventricular septal defect (VSD), closure, aortic arch reconstructions and pulmonary arterioplasty (tetralogy of Fallot repair). Four (4.3%) had transient heart block, one had complete heart block needing a permanent pacemaker. A residual shunt was present in less than 5% of the VSD patients which spontaneously closed within 12 months. One patient of VSD repair had a significant residual shunt requiring redo surgery. The intra-operative ease of handling was rated as 9/9 in 92.3% of patients. None of the patients were noticed to develop patch leaks, aneurysmal dilatation or calcification on 12-month follow-up. Conclusions: This tissue engineered bovine pericardium is a safe and reliable prosthetic material for corrective congenital heart surgery in short-term period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.